History in our lifetime: The changing nature of refractory duodenal ulcer in the era of histamine H2 receptor antagonists

Digestive and Liver Disease

Volumn 35, Issue 8, 2003, Pages 529-536

  Bardhan, K D ^b   Nayyar, A K ^a,b   Royston, C ^b  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

^b Rotherham NHS Foundation Trust   (United Kingdom)

Author keywords

Duodenal ulcer; Histamine receptor antagonists; Ulcer refractoriness

Indexed keywords

BISMUTH CITRATE; CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG MEGADOSE; DUODENUM ULCER; ERADICATION THERAPY; FEMALE; FOLLOW UP; GASTRECTOMY; GASTROINTESTINAL ENDOSCOPY; GASTROJEJUNOSTOMY; HUMAN; INCIDENCE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PEPTIC ULCER BLEEDING; PROSPECTIVE STUDY; PUBLIC HOSPITAL; PYLOROPLASTY; RELAPSE; RISK REDUCTION; STOMACH ANTRUM RESECTION; TREATMENT OUTCOME; ULCER HEALING; ULCER PERFORATION; VAGOTOMY; COMPARATIVE STUDY; DRUG ADMINISTRATION; DRUG EFFECT; DRUG RESISTANCE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RECURRENT DISEASE; WOUND HEALING;

ADULT; CIMETIDINE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; DUODENAL ULCER; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; PEPTIC ULCER HEMORRHAGE; PEPTIC ULCER PERFORATION; PROSPECTIVE STUDIES; RANITIDINE; RECURRENCE; WOUND HEALING;

EID: 2142647371     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00269-X     Document Type: Article

References (29)

1. Bardhan KD. Refractory duodenal ulcer. Gut 1984;25:697-702.
2. Bardhan KD. Intermittent treatment of duodenal ulcer with cimetidine. Br Med J 1980;281:20-2.
3. Scott B, Atkinson M. Gastroenterology services; a regional review of changes over a five year period (1981-1986). Gut 1989;30:695-700.
4. Bardhan KD. Non-responders to cimetidine treatment - Part 2. In: Baron JH, editor, Cimetidine in the 80s, Edinburgh: Churchill Livingstone; 1981, pp. 95-112.
5. Pulvertaft CN. Comments on the incidence and natural history of gastric and duodenal ulcer. Br J Prev Soc Med 1959;13:131-8.
6. Meade TW, Arie THD, Brewis M, Bond DJ, Morris JN. Recent history of ischaemic heart disease and duodenal ulcers in doctors. Br Med J 1968;3:701-4.
7. Logan WPD, Cushion AA. In: Morbidity statistics from general practice, Vol. 1, N14 London: General Register Office, HMSO; 1958.
8. Office of Population Census and Surveys. In: Morbidity statistics from general practice 1970-1971, N26 London: HMSO; 1974.
9. Coggon D, Lambert P, Langman MJS. 20 years of hospital admissions for peptic ulcer in England and Wales. Lancet 1981;1:1302-4.
10. Katschinski BD, Logan RF. Changes in the birth cohort pattern of peptic ulcer mortality in England and Wales. Postgrad Med J 1991;57:825-8.
11. Bardhan KD, Dobrilla G. Refractory duodenal ulcer. In: Dobrilla G, Bardhan KD, Steele A, editors, Non-responders in gastroenterology: causes and treatment, Verona: Cortina International; 1991, pp. 71-110.
12. Fry J. Peptic ulcer: a profile. Br Med J 1964;2:809-12.
13. Griebe J, Bugge P, Gjorup T, Lauritzen T, Bonnievie O, Wulff HR. Long-term prognosis of duodenal ulcer; follow-up study and survey of doctors' estimates. Br Med J 1977;2:1572-4.
14. Neil GA. Do ulcers burn out or burn on? Managing duodenal ulcer diathesis in the Helicobacter pylori era. Am J Gastroenterol 1997;92:387-93.
15. Nwokolo CU, Gavey CJ, Smith JTL, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990;5:29-45.
16. Smith JTL, Gavey CJ, Nwokolo CU, Pounder RE. Tolerance during eight days of high dose H2 blockade; placebo-controlled studies of 24 h acidity and gastrin. Gut 1989;30:A147.
17. Delle Fave G, Annibale B, Pauti M, Corelo V, Pasquali A, D'Ambre G. The refractoriness to H2 antagonists in healing duodenal ulcer is due to the loss of their anti-secretory efficacy. Gastroenterology 1988;94:A94.
18. Naesdal J, Bianchi-Porro G, Petrillo M, Lazzaroni M, Hinchliffe RFC, et al. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial. Gut 1991;32:435-8.
19. Bardhan KD. Omeprazole in the management of refractory duodenal Scand J Gastroenterol 1989;24(Suppl. 166):63-73.
20. Treiber G. The impact of H . pylori eradication on peptic ulcer healing. Gut 1997;41(Suppl. 1):A92.
21. Bianchi Porro G, Parente F, Lazzaroni M. Short and long-term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut 1993;34:466-9.
22. Brunner G, Creutzfeldt W, Haarke U, Lamberts R. Omeprazole therapy in patients with peptic ulceration resistant to extended high dose ranitidine treatment. Digestion 1988;39:80-90.
23. Hirshowicz BI, Lanas A. Intractable and recurrent post-surgical peptic ulceration is due to aspirin abuse, much of it is surreptitious. Gastroenterology 1992;102:A84.
24. Lanas A, Ramacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcer. Gastroenterology 1995;109:1124-33.
25. Thomas E, Reddy KR. Non-healing duodenal ulcer due to candida. J Clin Gastroenterol 1983;5:55-8.
26. Kochar R, Singh S, Talwar P, Metha SK. Cimetidine-induced candidiasis in duodenal ulcer: clinical study. Gastrointest Endosc 1988;34:283-4.
27. The European Helicobacter pylori Study Group, Malfertheiner P. Current concepts in the management of Helicobacter pylori infection. Gut 1997;41:8-13.
28. Konar A, Das AS, De PK, Roy A, Mazumder DNG. Natural history of severe duodenal ulcer disease. Indian J Gastroenterol 1998;17:48-50.
29. Peura DA. The problem of Helicobacter pylori-negative idiopathic ulcer disease. Bailliere's Clin Gastroenterol 2000;14:109-17.